[Influence of androgens on the somatotrope axis: role in the therapy of postandropause osteoporosis?].
Androgens, via aromatization in estrogens, stimulate growth hormone secretion. Their influence on IGF1 (insulin-like growth factor 1, or somatomedin C) are not so clear. Some studies have observed an increase of IGF1 with testosterone therapy and some other not. The way of administration, per os or transdermic, may have an influence, like the hormonal substitutive therapy of postmenopausal women. Oral estrogen therapy decreases IGF1 levels in postmenopausal women and increases GH secretion. IG1 level is variably reduced, unaffected or increased by transdermal estrogen. High dose transdermal estrogen did not affect basal level of IGF1, but reduced the response of IGF1 to GH stimulation. Low dose transdermal estrogen did not alter either baseline or peak IGF1 level.
Bologne
J C
JC
CHU, Sart Tilman et Centre Interdisciplinaire de la Ménopause et de l'Andropause, Policliniques Brull.
Legros
J J
JJ
D000728:Androgens / Q000494:pharmacology / Q000627:therapeutic use*; D047649:Andropause; D013006:Growth Hormone / Q000097:blood / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000187:drug effects*; D008297:Male; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000494:pharmacology
D000728:Androgens; D013739:Testosterone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone